ArticleAACE endocrinology and diabetes
Reclassification of Hypophosphatemic Bone Disease as X-Linked Hypophosphatemia Following Genetic Testing in Adulthood.
Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: X-linked hypophosphatemia (XLH) is a disorder caused by a pathogenic variant in the phosphate-regulating endopeptidase homolog X-linked gene. This leads to increased fibroblast growth factor 23 synthesis, prompting renal phosphate wasting and hypophosphatemia. Adults with XLH present with osteomalacia, chronic musculoskeletal pain, enthesopathy, osteoarthritis, fractures, and pseudofractures. We present a patient initially diagnosed with hypophosphatemic, nonrachitic bone disease. However, later genetic testing identified a pathogenic phosphate-regulating endopeptidase homolog X-linked variant (c.1645+1G>A), establishing an XLH diagnosis. Case Report: A 50-year-old male was diagnosed with XLH through molecular testing at age 49. He was initially diagnosed at age 3 years with hypophosphatemic bone disease due to an unclear inheritance pattern. Treatment with phosphate and active vitamin D was started but discontinued at age 13 due to adverse effects, then resumed between ages 30 and 45. The patient presented with joint pain, abnormal gait, dental abscesses, and right hip replacement due to early-onset osteoarthritis with history of an atraumatic vertebral fracture at age 42. Labs showed hypophosphatemia, low tubular phosphate reabsorption, and elevated alkaline phosphatase and fibroblast growth factor 23. He was switched to burosumab therapy, resulting in clinical improvement. Discussion: This case underscores the diagnostic challenges of atypical XLH, particularly when X-linked inheritance patterns are absent. It illustrates the transformative role of molecular diagnostics in establishing diagnoses. It also reports on the impact of burosumab therapy when initiated in adults. Conclusion: This case demonstrates hallmark biochemical and radiological features of XLH, and the value of genetic testing in establishing a definitive diagnosis, particularly in individuals with atypical or nonclassical presentations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.